International Endovascular Corporation (IEVC) Launches to Advance Next-Generation Vascular Technologies

Company focused on acquiring, developing, and commercializing innovative medical device technologies for vascular disease

Carlsbad, CA – May 5, 2024

International Endovascular Corporation (IEVC), a medical technology company focused on advancing next-generation vascular therapies, today announced its formation. Founded in May 2024, IEVC is dedicated to identifying, acquiring, and commercializing differentiated medical device technologies that address unmet needs in the treatment of vascular disease.

IEVC is operated by CyMeda, Inc., a developer of laser and light-based technologies founded in 2020. The company leverages CyMeda’s technical infrastructure, regulatory expertise, and operational capabilities to efficiently evaluate, advance, and selectively commercialize innovative products through a capital-efficient operating model.

IEVC is led by founder and Chief Executive Officer Dean Irwin, an experienced medical device executive with a track record in the development and commercialization of vascular technologies. The leadership team includes former key personnel from Ra Medical Systems, bringing deep expertise in laser-based therapies and interventional device markets.

The company has particular expertise in laser-based technologies, including excimer laser applications for vascular intervention.

“There remains significant unmet need in the treatment of vascular disease, particularly in technologies that can safely and effectively address complex lesions,” said Dean Irwin, Founder and CEO of IEVC. “We created IEVC to identify and advance differentiated technologies that can improve patient outcomes while delivering value to physicians and healthcare systems.”

The global burden of vascular disease continues to grow, driven by aging populations and increasing prevalence of conditions such as peripheral artery disease (PAD). IEVC is focused on technologies that enable improved vessel preparation, plaque modification, and minimally invasive treatment approaches.

The company is actively evaluating acquisition and partnership opportunities, with a focus on clinically validated technologies that can benefit from focused development, capital-efficient commercialization, and strategic positioning. IEVC is structured to operate with a streamlined infrastructure, enabling rapid execution and alignment with potential strategic partners.

“Our approach is to combine proven technology with experienced execution,” Irwin added. “By bringing together the right assets, team, and infrastructure, we believe we can accelerate the adoption of impactful therapies and unlock their full clinical and commercial potential, while maintaining a disciplined and capital-efficient approach to development and commercialization.”

IEVC’s strategy includes:

- Acquisition of underutilized or under-commercialized medical technologies

- Advancement of clinical and regulatory pathways

- Reintroduction and scaling of proven technologies

- Exploration of new applications across multiple vascular indications

About International Endovascular Corporation (IEVC)

International Endovascular Corporation (IEVC) is a medical technology company focused on acquiring, developing, and commercializing innovative solutions for the treatment of vascular disease. Founded in 2024 and operated by CyMeda, Inc., the company leverages deep expertise in laser-based therapies, interventional devices, and clinical execution to advance next-generation vascular technologies.

Contact:

Dean Irwin, CEO

dean.irwin@ievcorp.com